中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
29期
29-31
,共3页
徐国辉%周存才%周峥%何均%魏小勇%徐宗全
徐國輝%週存纔%週崢%何均%魏小勇%徐宗全
서국휘%주존재%주쟁%하균%위소용%서종전
原发性肝癌%脾功能亢进%肝癌切除术%全脾切除术
原髮性肝癌%脾功能亢進%肝癌切除術%全脾切除術
원발성간암%비공능항진%간암절제술%전비절제술
Primary hepatocellular%Hypersplenism%Liver cancer resection%Splenectomy
目的:探讨临床治疗原发性肝癌合并脾功能亢进的有效方案。方法:回顾分析163例原发性肝癌合并脾功能亢进患者的临床资料,根据治疗方案将上述患者分为观察组(n=83)与对照组(n=80),观察组接受肝癌切除术联合全脾切除术治疗,对照组仅接受肝癌切除术治疗。结果:(1)两组患者术中出血量、输血量比较差异无统计学意义(P>0.05)。(2)术前,两组患者红细胞(RBC)、白细胞(WBC)、血小板(PLT)比较差异无统计学意义(P>0.05);术后2个月,观察组WBC、PLT显著高于对照组(P<0.05),两组患者RBC比较差异无统计学意义(P>0.05)。(3)术前,两组患者CD4、CD8、CD4/CD8比较差异无统计学意义(P>0.05);术后2个月,观察组CD4、CD4/CD8显著高于对照组(P<0.05),CD8显著低于对照组(P<0.05)。(4)两组患者并发症发生率、病死率比较差异无统计学意义(P>0.05)。结论:肝癌切除术联合全脾切除术是治疗原发性肝癌合并脾功能亢进的有效方案,该方案值得临床应用与推广。
目的:探討臨床治療原髮性肝癌閤併脾功能亢進的有效方案。方法:迴顧分析163例原髮性肝癌閤併脾功能亢進患者的臨床資料,根據治療方案將上述患者分為觀察組(n=83)與對照組(n=80),觀察組接受肝癌切除術聯閤全脾切除術治療,對照組僅接受肝癌切除術治療。結果:(1)兩組患者術中齣血量、輸血量比較差異無統計學意義(P>0.05)。(2)術前,兩組患者紅細胞(RBC)、白細胞(WBC)、血小闆(PLT)比較差異無統計學意義(P>0.05);術後2箇月,觀察組WBC、PLT顯著高于對照組(P<0.05),兩組患者RBC比較差異無統計學意義(P>0.05)。(3)術前,兩組患者CD4、CD8、CD4/CD8比較差異無統計學意義(P>0.05);術後2箇月,觀察組CD4、CD4/CD8顯著高于對照組(P<0.05),CD8顯著低于對照組(P<0.05)。(4)兩組患者併髮癥髮生率、病死率比較差異無統計學意義(P>0.05)。結論:肝癌切除術聯閤全脾切除術是治療原髮性肝癌閤併脾功能亢進的有效方案,該方案值得臨床應用與推廣。
목적:탐토림상치료원발성간암합병비공능항진적유효방안。방법:회고분석163례원발성간암합병비공능항진환자적림상자료,근거치료방안장상술환자분위관찰조(n=83)여대조조(n=80),관찰조접수간암절제술연합전비절제술치료,대조조부접수간암절제술치료。결과:(1)량조환자술중출혈량、수혈량비교차이무통계학의의(P>0.05)。(2)술전,량조환자홍세포(RBC)、백세포(WBC)、혈소판(PLT)비교차이무통계학의의(P>0.05);술후2개월,관찰조WBC、PLT현저고우대조조(P<0.05),량조환자RBC비교차이무통계학의의(P>0.05)。(3)술전,량조환자CD4、CD8、CD4/CD8비교차이무통계학의의(P>0.05);술후2개월,관찰조CD4、CD4/CD8현저고우대조조(P<0.05),CD8현저저우대조조(P<0.05)。(4)량조환자병발증발생솔、병사솔비교차이무통계학의의(P>0.05)。결론:간암절제술연합전비절제술시치료원발성간암합병비공능항진적유효방안,해방안치득림상응용여추엄。
Objective:To investigate the effective regimen for primary hepatocellular carcinoma with hypersplenism.Method:The clinical data of 163 cases of primary hepatocellular carcinoma with hypersplenism were analyzed retrospectively.According to the surgical regimen,these patients were divided into an observation group(n=83)and a control group(n=80),and the observation group received liver cancer resection combined with splenectomy,while the control group received liver cancer resection only.Result:(1)No significant differences were found in perioperative blood loss and blood transfusion volume between the 2 groups(P>0.05).(2)Before surgery,no significant differences were found in red blood cell(RBC), white blood cell(WBC)and platelet(PLT)between the 2 groups(P>0.05). 2 months after surgery,the WBC and PLT in the observation group were statistically higher than those in the control group respectively(P<0.05),while no significant difference in RBC was found between the 2 groups(P>0.05).(3) Before surgery,no significant differences were found in CD4,CD8 and CD4/CD8 between the 2 groups(P>0.05). 2 months after surgery,the CD4 and CD4/CD8 in the observation group were statistically higher than those in the control group respectively(P<0.05),while the CD8 was lower than that in the control group(P<0.05).(4)No significant differences were found in complication rate and mortality rate between the 2 groups(P>0.05).Conclusion:The liver cancer resection combined with splenectomy is an effective regimen for primary hepatocellular carcinoma with hypersplenism,and this surgical regimen is worthy of being applied and popularized.